American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献_第6页

Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines. 加强早期乳腺癌患者的生存能力：以证据为基础的策略、监测测试和成像指南》（Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines）。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_432564

Mitchell J Elliott, Sherry Shen, Diana L Lam, Thelma Brown, Marissa B Lawson, Neil M Iyengar, David W Cescon

引用次数: 0

Common Sense Oncology: Equity, Value, and Outcomes That Matter. 肿瘤学常识：公平、价值和重要的结果。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_100039

Brooke E Wilson, Manju Sengar, Michelle Tregear, Winette T A van der Graaf, Nicolò Matteo Luca Battisti, Degi Laszlo Csaba, Enrique Soto-Perez-de-Celis, Bishal Gyawali, Christopher M Booth

引用次数: 0

Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. 神经纤维瘤病 1 型相关恶性周围神经鞘瘤的现代治疗方法。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_432242

Angela C Hirbe, Carina A Dehner, Eva Dombi, Vanessa Eulo, Andrea M Gross, Taylor Sundby, Alexander J Lazar, Brigitte C Widemann

引用次数: 0

Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches. 让我们对话：肿瘤学中的重病沟通：定义、障碍和成功方法。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_431352

Danielle M Shilling, Christopher R Manz, Jacob J Strand, Manali I Patel

{"title":"Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches.","authors":"Danielle M Shilling, Christopher R Manz, Jacob J Strand, Manali I Patel","doi":"10.1200/EDBK_431352","DOIUrl":"10.1200/EDBK_431352","url":null,"abstract":"Serious illness communications are crucial elements of care delivery for patients with cancer. High-quality serious illness communications are composed of open, honest discussions between patients, caregivers, and clinicians regarding patient's communication preferences, expected illness trajectory, prognosis, and risks and benefits of any recommended care. High-quality communication ideally starts at the time of a patients' cancer diagnosis, allows space for and response to patient emotions, elicits patients' values and care preferences, and is iterative and longitudinal. When integrated into cancer care, such communication can result in improved patient experiences with their care, care that matches patients' goals, and reduced care intensity at the end of life. Despite national recommendations for routine integration of these communication into cancer care, a minority of patients with cancer receive such communication. In this chapter, we describe elements of high-quality serious illness communication, patient-, clinician-, institution-, and payer-level barriers, and successful strategies that can routinely integrate such communication into cancer care delivery.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e431352"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors. 针对表皮生长因子受体突变肿瘤的非小细胞肺癌患者的新治疗方案。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI: 10.1200/EDBK_432516

Stephanie P L Saw, Xiuning Le, Lizza E L Hendriks, Jordi Remon

引用次数: 0

Integrating Palliative Care Into the Management of Genitourinary Malignancies. 将姑息治疗融入泌尿生殖系统恶性肿瘤的治疗中。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI: 10.1200/EDBK_438644

Eva K Masel, Joachim Baer, Claudia Wenzel

{"title":"Integrating Palliative Care Into the Management of Genitourinary Malignancies.","authors":"Eva K Masel, Joachim Baer, Claudia Wenzel","doi":"10.1200/EDBK_438644","DOIUrl":"10.1200/EDBK_438644","url":null,"abstract":"Palliative care (PC) plays a critical role in managing the difficulties associated with genitourinary malignancies. Its primary aim is to improve the overall health of patients, provide support to both patients and their caregivers, and help individuals to navigate the complex decisions about treatment and end-of-life care. PC takes a holistic approach to patient care, recognizing that genitourinary malignancies affect multiple aspects of a person's life. By addressing physical, emotional, social, and spiritual needs, PC aims to provide comprehensive support that is consistent with the patient's values and preferences. The goal is to optimize comfort, minimize distress, and enhance the patient's quality of life throughout the course of the illness. PC is not a one-off intervention, but an ongoing source of support. This article aims to provide a thorough overview of the critical elements involved in addressing the challenges posed by genitourinary cancers, emphasizing the importance of palliative interventions. We will highlight the multifaceted aspects of care and explore strategies to optimize the overall well-being of patients throughout the course of treatment for genitourinary malignancies.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e438644"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements and Challenges in the Treatment of AML. 治疗急性髓细胞白血病的进展与挑战。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI: 10.1200/EDBK_438662

Yasmin Abaza, Christine McMahon, Jacqueline S Garcia

{"title":"Advancements and Challenges in the Treatment of AML.","authors":"Yasmin Abaza, Christine McMahon, Jacqueline S Garcia","doi":"10.1200/EDBK_438662","DOIUrl":"10.1200/EDBK_438662","url":null,"abstract":"The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based induction chemotherapy (for all fit patients) or a single-agent hypomethylating agent (in unfit patients or those 75 years and older). While assessing patient fitness remains important, characterizing the disease biology has become critical to select the optimal initial therapy for each patient with more options available. FLT3 inhibitors, gemtuzumab ozogamicin, and CPX-351 have been shown to improve outcomes for specific subsets of patients. Venetoclax (VEN) with a hypomethylating agent (HMA) is the standard-of-care frontline regimen for most older patients, except perhaps for those with an IDH1 mutation where ivosidenib with azacitidine may also be considered. On the basis of the success seen with HMA/VEN in older patients, there is now increasing interest in incorporating VEN into frontline regimens in younger patients, with promising data from multiple early phase studies. This article focuses on recent updates and ongoing challenges in the management of AML, with a particular focus on the ongoing challenge of secondary AML and considerations regarding the selection of initial therapy in younger patients. An overview of common side effects and toxicities associated with targeted therapies is also presented here, along with recommended strategies to mitigate these risks.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e438662"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-Escalation of Therapy for Prostate Cancer. 减轻前列腺癌的治疗。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-01-01 DOI: 10.1200/EDBK_430466

Tarik Esen, Baris Esen, Kosj Yamaoh, Ugur Selek, Derya Tilki

{"title":"De-Escalation of Therapy for Prostate Cancer.","authors":"Tarik Esen, Baris Esen, Kosj Yamaoh, Ugur Selek, Derya Tilki","doi":"10.1200/EDBK_430466","DOIUrl":"10.1200/EDBK_430466","url":null,"abstract":"Prostate cancer (PCa) is the second most commonly diagnosed cancer in men with around 1.4 million new cases every year. In patients with localized disease, management options include active surveillance (AS), radical prostatectomy (RP; with or without pelvic lymph node dissection), or radiotherapy to the prostate (with or without pelvic irradiation) with or without hormonotherapy. In advanced disease, treatment options include systemic treatment(s) and/or treatment to primary tumour and/or metastasis-directed therapies (MDTs). Specifically, in advanced stage, the current trend is earlier intensification of treatment such as dual or triple combination systemic treatments or adding treatment to primary and MDT to systemic treatment. However, earlier treatment intensification comes with the cost of increased morbidity and mortality resulting from drug-/treatment-related side effects. The main goal is and should be to provide the best possible care and oncologic outcomes with minimum possible side effects. This chapter will explore emerging possibilities to de-escalate treatment in PCa driven by enhanced insights into disease biology and the natural course of PCa such as AS in intermediate-risk disease or salvage versus adjuvant radiotherapy in post-RP patients. Considerations arising from advancements in PCa imaging and technological advancements in surgical and radiation therapy techniques including omitting pelvic lymph node dissection in the era of prostate-specific membrane antigen positron emitting tomography, the potential of MDT to delay/omit systemic treatment in metachronous oligorecurrence, and the efficacy of hypofractionation schemes compared with conventional fractionated radiotherapy will be discussed.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 2","pages":"e430466"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons. 泌尿生殖道小细胞癌的新见解：从诊断到新的治疗前景。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-01-01 DOI: 10.1200/EDBK_430336

Ross S Liao, Hui Ting Ruan, Albert Jang, Melissa Huynh, Rosa Nadal Rios, Jean H Hoffman-Censits, Shuanzeng Wei, Omar Y Mian, Pedro C Barata

{"title":"Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons.","authors":"Ross S Liao, Hui Ting Ruan, Albert Jang, Melissa Huynh, Rosa Nadal Rios, Jean H Hoffman-Censits, Shuanzeng Wei, Omar Y Mian, Pedro C Barata","doi":"10.1200/EDBK_430336","DOIUrl":"10.1200/EDBK_430336","url":null,"abstract":"Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate, but case reports of primary SCC of the kidney, ureter, and urethra also exist. The majority of patients present with gross hematuria, irritative or obstructive urinary symptoms, and symptoms of locoregionally advanced or metastatic disease at initial presentation. SCC of the bladder presents with nodal or metastatic involvement in the majority of cases and requires the use of platinum-based chemotherapy in combination with surgery and/or radiation. SCC of the prostate is most commonly seen in the metastatic castrate-resistant setting, and aggressive variant disease presents with a greater propensity for visceral metastases, osteolytic lesions, and relatively low serum prostate-specific antigen for volume of disease burden. Multiple retrospective and prospective randomized studies support the use of a multimodal approach combining platinum-based systemic therapy regimens with radiation and/or surgery for localized disease. This evidence-based strategy is reflected in multiple consensus guidelines. Emerging data suggest that small-cell bladder and prostate cancers transdifferentiate from a common progenitor of conventional urothelial bladder carcinoma and prostatic acinar adenocarcinoma, respectively. Areas of active basic research include efforts to identify the key genetic and epigenetic drivers involved in the emergence of small cell cancers to exploit them for novel therapies. Here, we review these efforts, discuss diagnosis and currently supported management strategies, and summarize ongoing clinical trials evaluating novel therapies to treat this rare, aggressive GU cancer.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 ","pages":"e430336"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139098902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Oligometastatic GI Cancers. 治疗寡转移性消化道癌症。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-01-01 DOI: 10.1200/EDBK_430152

Clayton T Marcinak, Patrick B Schwartz, Mustafa M Basree, Newton Hurst, Michael Bassetti, Jeremy D Kratz, Nataliya V Uboha

{"title":"Treatment of Oligometastatic GI Cancers.","authors":"Clayton T Marcinak, Patrick B Schwartz, Mustafa M Basree, Newton Hurst, Michael Bassetti, Jeremy D Kratz, Nataliya V Uboha","doi":"10.1200/EDBK_430152","DOIUrl":"https://doi.org/10.1200/EDBK_430152","url":null,"abstract":"Oligometastatic state is believed to potentially represent a transitional stage between early, locoregional state disease and widely metastatic disease. Historically, locoregional approaches, particularly in advanced colorectal cancers, have demonstrated efficacy in select patients with limited burden of metastatic disease. Recent strides in systemic therapies, including biomarker-based treatments and immunotherapy, alongside innovations in surgical techniques and novel locoregional approaches such as stereotactic radiotherapy and ablation, have ushered in a new era of therapeutic possibilities across all oligometastatic GI cancers. Despite these advancements, there remains a significant gap in high-quality prospective evidence guiding patient selection and treatment decisions across various disease types. Ongoing clinical trials are anticipated to provide crucial insights into oligometastatic states, fostering the refinement of disease-specific oligometastatic state definitions and treatment algorithms. This article reviews existing data on the management of oligometastatic GI cancer, summarizes current state of knowledge for each disease state, and provides updates on ongoing studies in this space.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 ","pages":"e430152"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0